Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing L Rasche, SS Chavan, OW Stephens, PH Patel, R Tytarenko, C Ashby, ... Nature communications 8 (1), 268, 2017 | 360 | 2017 |
Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma D Hose, T Rème, T Hielscher, J Moreaux, T Messner, A Seckinger, ... Haematologica 96 (1), 87, 2011 | 231 | 2011 |
Low expression of hexokinase-2 is associated with false-negative FDG–positron emission tomography in multiple myeloma L Rasche, E Angtuaco, JE McDonald, A Buros, C Stein, C Pawlyn, ... Blood, The Journal of the American Society of Hematology 130 (1), 30-34, 2017 | 217 | 2017 |
Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma N Weinhold, C Ashby, L Rasche, SS Chavan, C Stein, OW Stephens, ... Blood, The Journal of the American Society of Hematology 128 (13), 1735-1744, 2016 | 214 | 2016 |
The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor AC Sprynski, D Hose, L Caillot, T Réme, JD Shaughnessy Jr, B Barlogie, ... Blood, The Journal of the American Society of Hematology 113 (19), 4614-4626, 2009 | 204 | 2009 |
Induction of angiogenesis by normal and malignant plasma cells D Hose, J Moreaux, T Meissner, A Seckinger, H Goldschmidt, A Benner, ... Blood, The Journal of the American Society of Hematology 114 (1), 128-143, 2009 | 151 | 2009 |
Functional expression of dental plaque microbiota SN Peterson, T Meissner, AI Su, E Snesrud, AC Ong, NJ Schork, WA Bretz Frontiers in Cellular and infection microbiology 4, 108, 2014 | 120 | 2014 |
Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma D Hose, T Rème, T Meissner, J Moreaux, A Seckinger, J Lewis, V Benes, ... Blood, The Journal of the American Society of Hematology 113 (18), 4331-4340, 2009 | 115 | 2009 |
Clinical and prognostic role of annexin A2 in multiple myeloma A Seckinger, T Meiβner, J Moreaux, D Depeweg, J Hillengass, K Hose, ... Blood, The Journal of the American Society of Hematology 120 (5), 1087-1094, 2012 | 93 | 2012 |
Omics Pipe: a community-based framework for reproducible multi-omics data analysis KM Fisch, T Meißner, L Gioia, JC Ducom, TM Carland, S Loguercio, AI Su Bioinformatics 31 (11), 1724-1728, 2015 | 92 | 2015 |
Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis A Seckinger, T Meissner, J Moreaux, H Goldschmidt, GM Fuhler, ... Oncogene 28 (44), 3866-3879, 2009 | 92 | 2009 |
Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays K Mahtouk, J Moreaux, D Hose, T Rème, T Meißner, M Jourdan, JF Rossi, ... BMC cancer 10, 1-18, 2010 | 80 | 2010 |
Gene expression profiling in multiple myeloma—reporting of entities, risk, and targets in clinical routine T Meißner, A Seckinger, T Rème, T Hielscher, T Möhler, K Neben, ... Clinical Cancer Research 17 (23), 7240-7247, 2011 | 57 | 2011 |
Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6 M Witzens-Harig, D Hose, S Jünger, C Pfirschke, N Khandelwal, ... Blood, The Journal of the American Society of Hematology 121 (22), 4493-4503, 2013 | 53 | 2013 |
miRNAs in multiple myeloma–a survival relevant complex regulator of gene expression A Seckinger, T MeiΔner, J Moreaux, V Benes, J Hillengass, M Castoldi, ... Oncotarget 6 (36), 39165, 2015 | 52 | 2015 |
Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma JS Waizenegger, I Ben-Batalla, N Weinhold, T Meissner, M Wroblewski, ... Leukemia 29 (3), 696-704, 2015 | 47 | 2015 |
Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression N Li, DC Johnson, N Weinhold, JB Studd, G Orlando, F Mirabella, ... Nature communications 7 (1), 13656, 2016 | 43 | 2016 |
Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1 V Wagner, D Hose, A Seckinger, L Weiz, T Meißner, T Rème, I Breitkreutz, ... Oncotarget 5 (21), 10237, 2014 | 42 | 2014 |
The 7p15. 3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells N Weinhold, T Meissner, DC Johnson, A Seckinger, J Moreaux, A Försti, ... Haematologica 100 (3), e110, 2015 | 34 | 2015 |
Immunomodulatory drugs thalidomide and lenalidomide affect osteoblast differentiation of human bone marrow stromal cells in vitro A Bolomsky, M Schreder, T Meißner, D Hose, H Ludwig, S Pfeifer, N Zojer Experimental hematology 42 (7), 516-525, 2014 | 32 | 2014 |